Johnson & Johnson was one of the notable exceptions, lowering its forecast for 2020 sales revenue, mostly due to the pandemic’s effects on its device business.
Unlike medical devicemakers — many of which either suspended or withdrew their 2020 financial guidance due to a lack of elective surgeries — drugmakers have so far been minimally affected financially by the COVID-19 pandemic.
Drugmakers with products that are mostly administered in hospitals saw bigger sales losses than those with products used outside hospitals, S&P global found. Drugmakers that sell pills instead of injections also fared better.
The top 15 drugmakers and the changes made to their 2020 sales revenue guidance:
- Johnson & Johnson — Lowered
- Roche — No change
- Pfizer — No change
- Novartis — No change
- Merck — Lowered
- Novo Nordisk — No change
- Eli Lilly — No change
- AstraZeneca — No change
- Bristol Myers Squibb — No change
- Amgen — No change
- AbbVie — No change
- Sanofi — No change
- GlaxoSmithKline — No change
- Gilead Sciences — No change
- Vertex Pharmaceuticals — Raised
More articles on pharmacy:
Trump inks deal to create the nation’s first strategic stockpile of COVID-19 drugs
Gilead to donate 300,000 more remdesivir doses to US hospitals
Moncef Slaoui resigns from Moderna board, divests $10M in stock
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.